Table 1. Basic Characteristics of Patient Groupsa.
| healthy | healthy | cirrhosis | cirrhosis | HCC | HCC | |
|---|---|---|---|---|---|---|
| 1 | 2 | 1 | 2 | 1 | 2 | |
| male [%] | 80 | 80 | 80 | 80 | 80 | 80 |
| race (CA/AA) | 3/2 | 3/2 | 3/2 | 3/2 | 3/2 | 3/2 |
| age | 56 ± 1 | 57 ± 4 | 55 ± 2 | 56 ± 4 | 57 ± 2 | 55 ± 4 |
| MELD | n/a | n/a | 10 ± 6 | 11 ± 5 | 10 ± 5 | 10 ± 4 |
| INR | n/a | n/a | 1.2 ± 0.3 | 1.2 ± 0.2 | 1.2 ± 0.3 | 1.2 ± 0.2 |
| albumin [g/dL] | n/a | n/a | 3.4 ± 0.7 | 3.3 ± 0.4 | 3.2 ± 0.6 | 3.5 ± 0.8 |
| AFP [ng/mL] | n/a | n/a | 15.5 ± 64.8 | 8.4 ± 15.3 | 22.3 ± 11.0 | 16.2 ± 9.2 |
| bilirubin [mg/dL] | n/a | n/a | 1.5 ± 1.1 | 2.5 ± 1.7 | 2.1 ± 1.0 | 1.5 ± 0.5 |
| AST/ALT | n/a | n/a | 1.3 ± 0.7 | 1.9 ± 0.3 | 1.3 ± 0.5 | 1.4 ± 1.1 |
| alkaline phosphatase [IU/L] | n/a | n/a | 143 ± 30 | 114 ± 40 | 132 ± 75 | 94 ± 119 |
| creatinine [mg/dL] | n/a | n/a | 0.9 ± 0.1 | 0.8 ± 0.1 | 0.7 ± 0.0 | 0.8 ± 0.3 |
| BUN [mg/dL] | n/a | n/a | 11 ± 1 | 9 ± 3 | 10 ± 3 | 13 ± 2 |
| WBC count [103/mm3] | n/a | n/a | 8.0 ± 2.1 | 5.7 ± 1.7 | 5.0 ± 0.9 | 5.9 ± 1.4 |
| lymphocytes [%] | n/a | n/a | 30.2 ± 9.5 | 37.3 ± 5.0 | 25.9 ± 16.1 | 32.0 ± 23.2 |
| neutrophils [%] | n/a | n/a | 57.5 ± 12.6 | 47.0 ± 4.7 | 60.3 ± 13.9 | 52.3 ± 28.8 |
| platelet count [103/mm3] | n/a | n/a | 70 ± 17 | 143 ± 52 | 86 ± 73 | 78 ± 24 |
| ascites (yes/no) | n/a | n/a | 2/3 | 2/3 | 2/3 | 1/4 |
a
Values are expressed as median ± interquartile range. There are no significant differences among groups in the listed parameters (P > 0.05). Abbreviations: HCC, hepatocellular carcinoma; CA, Caucasian; AA, African American; MELD, Model for End-Stage Liver Disease; INR, International Normalized Ratio for prothrombin time; AFP, Alpha-fetoprotein; AST/ALT, aspartate/alanine transaminase ratio; BUN, blood urea nitrogen; WBC, white blood cell.